Hidoc Dr | Medical Learning App for Doctors

Today's Updates

Depemokimab Year 1 Remission Linked to Better Year 2 Asthma Outcomes Michael Wechsler, MD, MSc

Published Date: 31 Oct 2026

Michael Wechsler, MD, reports 59% of patients in clinical remission with twice-yearly depemokimab at year 1 maintained it at year 2 in SWIFT/AGILE.

Experts Discuss PAH Treatment Selection and Access

Published Date: 31 Oct 2026

Experts Discuss PAH Treatment Selection and Access

HCPLive Five at CHEST 2026

Published Date: 31 Oct 2026

HCPLive Five at CHEST 2026

Blood-Based Biomarkers for Monitoring Treatment Response in Multiple Sclerosis Louie Pasculli, Kim Henriksen, PhD

Published Date: 31 Oct 2026

Kim Henriksen, PhD, discusses research evaluating blood-based biomarkers of blood-brain barrier remodeling and immune cell activity in multiple sclerosis, including their potential to track treatment responses and inform future biomarker development.

World Stroke Day 2026: Closing the Gap Between Stroke Onset and the Emergency Call Number Isabella Ciccone, MPH, Brian Snelling, MD

Published Date: 31 Oct 2026

Brian Snelling, MD, director of the stroke program at Marcus Neuroscience Institute discussed delays in calling 911 after stroke onset, gaps in awareness of atypical symptoms, and how to reach underserved populations.

Incorporating the Updated AAN/AHS Migraine Prevention Guideline Into Practice Isabella Ciccone, MPH, Ann Pakalnis, MD

Published Date: 31 Oct 2026

The clinical professor of neurology and pediatrics at The Ohio State University Wexner Medical Center discussed payer step therapy, earlier preventive treatment, and questions the updated guideline leaves open.

World Stroke Day: Preventing Perioperative Stroke With Predictive Tools Marco Meglio, Shadi Yaghi, MD

Published Date: 31 Oct 2026

Shadi Yaghi, MD, FAHA, Chair of Neurology at Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center, discusses a new calculator that predicts stroke risk within 30 days of a procedure.

Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years David Rubin, MD

Published Date: 31 Oct 2026

David Rubin, MD, discusses QUASAR extension data showing most patients in histologic remission on guselkumab stayed there through 3 years of maintenance.

No New Safety Signals Over 3 Years in HS With Bimekizumab: Amit Garg, MD Amit Garg, MD

Published Date: 31 Oct 2026

Amit Garg, MD, discusses 3-year pooled BE HEARD safety data on bimekizumab in moderate to severe hidradenitis suppurativa from EADV 2026.

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

Published Date: 31 Oct 2026

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

Knowledge Hub

Oncology

Precision Selection of Cancer Surgery Versus Organ-Preserving Treatment Using Patient-Specific Functional Priorities

A clinical review of individualized cancer treatment decisions balancing oncological control with organ preservation and patient-specific functional priorities.

Oncology

Pathophysiology of Tumor Interstitial Fluid Accumulation

A medical review of the mechanisms, clinical effects, diagnosis, and management of tumor interstitial fluid accumulation.

Oncology

Tumor Metabolic Waste Products as Markers of Treatment Adaptation

A medical review of tumor-derived metabolic waste products as dynamic biomarkers for treatment response, resistance, toxicity, and therapeutic adaptation.

Oncology

Coordinating Supportive Care During Cancer Treatment Breaks

A clinical review of multidisciplinary strategies for maintaining symptom control, safety, function, and continuity during cancer treatment breaks.

Oncology

KOL Videos

Hidoc Dr| Hidoc- US| Hidoc - Doctor Netwoking Platform| Educational resource for HCPs

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Your one-stop Solution for MEDICAL LEARNING & UPDATES

Depemokimab Year 1 Remission Linked to Better Year 2 Asthma Outcomes Michael Wechsler, MD, MSc

Experts Discuss PAH Treatment Selection and Access

HCPLive Five at CHEST 2026

Blood-Based Biomarkers for Monitoring Treatment Response in Multiple Sclerosis Louie Pasculli, Kim Henriksen, PhD

World Stroke Day 2026: Closing the Gap Between Stroke Onset and the Emergency Call Number Isabella Ciccone, MPH, Brian Snelling, MD

Incorporating the Updated AAN/AHS Migraine Prevention Guideline Into Practice Isabella Ciccone, MPH, Ann Pakalnis, MD

World Stroke Day: Preventing Perioperative Stroke With Predictive Tools Marco Meglio, Shadi Yaghi, MD

Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years David Rubin, MD

No New Safety Signals Over 3 Years in HS With Bimekizumab: Amit Garg, MD Amit Garg, MD

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

Knowledge Hub

Precision Selection of Cancer Surgery Versus Organ-Preserving Treatment Using Patient-Specific Functional Priorities

Pathophysiology of Tumor Interstitial Fluid Accumulation

Tumor Metabolic Waste Products as Markers of Treatment Adaptation

Coordinating Supportive Care During Cancer Treatment Breaks

Pediatric Cancer Cell Line Authentication and Reproducibility

Case-Based Learning: Fever During Targeted Cancer Therapy Without Infection

Tumor Clonal Evolution Through Single-Cell Genomics

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Page Views

Your one-stop Solution for MEDICAL LEARNING & UPDATES

Depemokimab Year 1 Remission Linked to Better Year 2 Asthma Outcomes Michael Wechsler, MD, MSc

Experts Discuss PAH Treatment Selection and Access

HCPLive Five at CHEST 2026

Blood-Based Biomarkers for Monitoring Treatment Response in Multiple Sclerosis Louie Pasculli, Kim Henriksen, PhD

World Stroke Day 2026: Closing the Gap Between Stroke Onset and the Emergency Call Number Isabella Ciccone, MPH, Brian Snelling, MD

Incorporating the Updated AAN/AHS Migraine Prevention Guideline Into Practice Isabella Ciccone, MPH, Ann Pakalnis, MD

World Stroke Day: Preventing Perioperative Stroke With Predictive Tools Marco Meglio, Shadi Yaghi, MD

Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years David Rubin, MD

No New Safety Signals Over 3 Years in HS With Bimekizumab: Amit Garg, MD Amit Garg, MD

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

Knowledge Hub

Precision Selection of Cancer Surgery Versus Organ-Preserving Treatment Using Patient-Specific Functional Priorities

Pathophysiology of Tumor Interstitial Fluid Accumulation

Tumor Metabolic Waste Products as Markers of Treatment Adaptation

Coordinating Supportive Care During Cancer Treatment Breaks

Pediatric Cancer Cell Line Authentication and Reproducibility

Case-Based Learning: Fever During Targeted Cancer Therapy Without Infection

Tumor Clonal Evolution Through Single-Cell Genomics

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Verification

Welcome to Hidoc Dr.

Page Views